AstraZeneca is granted a preliminary injunction
17 February 2016
AstraZeneca has been granted another preliminary injunction against a generic version of Seroquel® Prolong. Plesner assisted AstraZeneca in the injunction proceedings.
The Danish Maritime and Commercial High Court has just given a ruling in a case between AstraZeneca and Hexal concerning infringement of AstraZeneca's patent for a sustained release formulation of quetiapine.
AstraZeneca was successful in all its claims and the Court prohibited future sales by Hexal A/S of the product Quetiapine "Hexal", a generic version of AstraZeneca's product Seroquel®Prolong.
AstraZeneca has previously been successful in similar cases against Orion Corporation and Orion Pharma A/S. However, in this case the Court also found that it has been proved on a balance of probabilities that AstraZeneca's patent is valid, which was not disputed during the first case.
Attorney and Partner Peter-Ulrik Plesner and Attorney Mette Hygum Clausen conducted the case on behalf of AstraZeneca.
AstraZeneca has previously been successful in similar cases against Orion Corporation and Orion Pharma A/S. However, in this case the Court also found that it has been proved on a balance of probabilities that AstraZeneca's patent is valid, which was not disputed during the first case.
Attorney and Partner Peter-Ulrik Plesner and Attorney Mette Hygum Clausen conducted the case on behalf of AstraZeneca.
